Itepekimab

DB16206Investigational

Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).

Mechanism: Pharmacologically active on Interleukin-33
Curator reviewed
Also known as: Immunoglobulin igg4 (230-proline), anti-(human interleukin 33) (human monoclonal regn3500 .gamma.4-chain), disulfide with human monoclonal regn3500 .kappa.-chain, dimer
Code names: REGN-3500 · SAR440340

Resolves to

Compound

UNIIWV9KZ9PS1ACAS2226742-52-3

Targets

O95760IL33

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Itepekimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account